Jonathan Leventhal is a Dermatology physician affiliated with Yale University. OpenAlex indexes 143 publications with 2,535 citations (h-index 24).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
15 York St
Lmp-5040
New Haven, CT 065103221
Telephone
203-785-4632Registry record last updated 10 Oct 2016.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year20252 payments
- Regeneron Healthcare Solutions, Inc.Program year20244 payments
- Regeneron Healthcare Solutions, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
36.4%Corticosteroid20.2%Triamcinolone Acetonide97%Fluocinolone Acetonide4%Part D<11 patientsInterleukin-4 Receptor alpha Antagonist10.6%Dupixent Pen84%Dupixent Syringe16%Part D<11 patients+ 4 more classes in this area
Anti-infectives
17.4%Azole Antifungal7.5%Ketoconazole100%Part D≥109 patientsTetracycline-class Drug3%Doxycycline Hyclate90%Minocycline Hcl10%Part D<11 patients+ 5 more classes in this area
Sensory organs
17%Corticosteroid17%Clobetasol Propionate48%Betamethasone Diprop Augmented36%Hydrocortisone13%Dexamethasone3%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy
Journal for ImmunoTherapy of Cancer
2024 - The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
American Journal of Clinical Dermatology
2024 - The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature
American Journal of Clinical Dermatology
2024 - Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors
Breast Cancer Research and Treatment
2024
Similar KOLs
Other experts from the same institution or the same specialty.
John Krystal, MD
Yale University
Lajos Pusztai, MD
Yale University
Lee Schwamm, MD
Yale University
Naftali Kaminski, MD
Yale University
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”